The forecast for beta-blocker sales in Canada reveals a consistent decline from 2024 to 2028, with values decreasing from $196.5 million in 2024 to $176.9 million by 2028. Compared to 2023, when sales were already showing signs of a moderate downturn, this forecast illustrates an overall 10% decline over the five-year period. Annually, this translates to an approximate compound annual growth rate (CAGR) of -2.6%, indicating a steady deceleration in market demand for these medicines.

Future trends to watch for include:

Increased generic competition potentially accelerating the decline in branded beta-blocker sales.
Potential impacts of healthcare policy changes in Canada affecting prescription practices for beta-blockers.
Emerging alternative treatments and technologies in cardiovascular care which could further influence market demand.